ArticleEJHaem2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at Relapse.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis.NPJ precision oncology · 2025Review
- Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at Relapse.EJHaem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in patients with aggressive-B-cell lymphoma. Methods: Patients were prospectively recruited from the 'standard-of-care' clinic based on high-risk clinical features. Using error-corrected, capture-based NGS of ctDNA, we profiled 17 patients receiving treatment for diffuse large B-cell lymphoma to determine the utility of molecular profiling and dynamic response assessment through to measurable residual disease (MRD) states. Results: Somatic mutations were detected at baseline in 17/17 patients, including 13 with phased variants that could be leveraged for enhanced assay sensitivity. Early molecular response (EMR; ≥ 2 log Conclusion: These data further support the potential utility of molecular lymphoma profiling by ctDNA analysis and the predictive value of EMR as reported by independent groups. We also posit that ctDNA alone is insufficient to diagnose late relapses, where shared mutations may associate with differential histopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.